glargine, both combined with lispro, mitigated eGFR decline in people with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)

Baseline characteristics play a significant role: Starting weight and BMI : Individuals with higher baseline body weight may experience more absolute weight loss initially Metabolic rate : Basal metabolic rate varies with age, sex, muscle mass, and genetic factors Insulin resistance severity : Those with greater insulin resistance may respond differently Concurrent medications : Some drugs (e.g., corticosteroids, certain antipsychotics) may counteract weight loss Lifestyle factors are equally important: Dietary adherence : Calorie intake and nutritional quality significantly impact results Physical activity levels : Regular exercise enhances weight loss and improves metabolic health Sleep quality : Poor sleep is associated with weight gain and reduced treatment efficacy Stress management : Chronic stress and elevated cortisol can impede weight loss Treatment-related factors include: Dose achieved : Higher doses (14 mg) generally produce greater weight loss than lower doses Treatment duration : Longer treatment periods typically yield more substantial results Tolerability : Gastrointestinal side effects may limit dose escalation in some patients Adherence : Consistent daily dosing is essential for optimal outcomes Additionally, underlying medical conditions such as hypothyroidism, polycystic ovary syndrome, or other endocrine disorders may influence weight loss velocity

Your doctor will monitor your treatment closely to ensure optimal safety and results
From March 21, a wave of affordable generic versions is expected to enter the market, significantly reducing costs and expanding access to treatment (1 Trusted Source Semaglutide Patent Expiry in India: 5000 Crore Pharma Business Opportunity Go to source)
Combined with semaglutide, even moderate alcohol consumption can produce dramatic bloating that lasts well into the next day